In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 147959-19-1, name is (S)-tert-Butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate, introducing its new discovery. Safety of (S)-tert-Butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate
Diastereoselective synthesis of D-threo-sphinganine, L-erythro-sphinganine and (?)-spisulosine through asymmetric alpha-hydroxylation of a higher homologue of Garner’s aldehyde
A diastereoselective route to the synthesis of D-threo-sphinganine, L-erythro-sphinganine and (?)-spisulosine from the higher homologue of Garner’s aldehyde prepared from L-aspartic acid is reported. While the starting material contains one of the stereocenters in the target molecules, the other is generated by proline-catalyzed asymmetric alpha-hydroxylation of the aldehyde function. The two diastereomers of sphinganine are prepared from the same starting material and using the same sequence of reactions, but for the proline isomer used as the catalyst. The method described is simple and efficient and can easily be extended for the synthesis of other sphingoid bases.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 147959-19-1, and how the biochemistry of the body works.Safety of (S)-tert-Butyl 2,2-dimethyl-4-(2-oxoethyl)oxazolidine-3-carboxylate
Reference£º
Oxazolidine – Wikipedia,
Oxazolidine | C3H2344NO – PubChem